Clinical Significance of Serum Type-III Procollagen Arninopropeptide in Hepatitis B Virus-Related Liver Diseases

References

• Seyer J M, Hutchenson E T, Kang AH. Collagen polymorphism in normal and cirrhotic human liver. J Clin Invest 1977; 59: 241–248
   PubMed Web of Science ®Google Scholar
• Rojkind M, Gambrone M A, Biempica L. Collagen types in normal and cirrhotic liver. Gastroen-terology 1979; 76: 710–719
   PubMed Web of Science ®Google Scholar
• Murata K, Kudo F, Motoyama T. Changes of collagen types at various stages of human liver cirrhosis. Hepatogastroenterology 1984; 31: 158–161
   PubMed Web of Science ®Google Scholar
• Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987; 252, C1–C9
   Google Scholar
• Hahn EG. Blood analysis for liver fibrosis. J Hepatol 1984; 1: 67–73
   Web of Science ®Google Scholar
• Colombo M, Annoni G, Donato M F, Conte D, Martines D, Zaramella M G, Bianchi P A, et al. Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology 1985; 5: 475–479
   PubMed Web of Science ®Google Scholar
• Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4: 830–834
   PubMed Web of Science ®Google Scholar
• Galambos M R, Collins D C, Galambos JT. A radioimmunoassay procedure for type III procollagen: its use in the detection of hepatic fibrosis. Hepatology 1985; 5: 38–42
   PubMedGoogle Scholar
• Niemela O, Risteli L, Sotaniemi E A, Risteli J. Aminoterminal propeptide of type III procollagen in serum in alcoholic liver disease. Gastroenterology 1983; 85: 254–259
   PubMed Web of Science ®Google Scholar
• Weigand K, Zaugg P Y, Frei A, Zimmermann A. Long-term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984; 4: 835–838
   PubMed Web of Science ®Google Scholar
• Trivedi P, Risteli J, Risteli L, Tanner M S, Bhave S, Pandit A N, Mowat AP. Serum type III procollagen and basement membrane proteins as non-invasive markers of hepatic pathology in Indian childhood cirrhosis. Hepatology 1987; 7: 1249–1253
   PubMedGoogle Scholar
• McCullough A J, Stassen W N, Wiesner R H, Czaja AJ. Serum type III procollagen peptide concentrations in severe chronic active hepatitis: relationship to cirrhosis and disease activity. Hepatology 1987; 7: 49–54
   PubMed Web of Science ®Google Scholar
• Torres-Salinas M, Pares A, Cacalleria J, Jimenez W, Heredia D, Bruguera M, Rodes J. Serum procollagen type III peptide as a marker of fibrogenesis in alcoholic hepatitis. Gastroenterology 1986; 90: 1241–1246
   PubMed Web of Science ®Google Scholar
• Bianchi L, Groote J D, Desmet V J, Gedigk P, Korb G, Popper H, Poulsen H, et al. Acute and chronic hepatitis revisited. Lancet 1977; 2: 914–919
   PubMed Web of Science ®Google Scholar
• Boyer JL. Chronic hepatitis—a perspective on classification and determinants of prognosis. Gastroenterology 1976; 70: 1161–1171
   PubMed Web of Science ®Google Scholar
• Rohde H, Vargas L, Hahn E, Kalbfleisch H, Bruguera M, Timpl R. Radioimmunoassay for type III procollagen peptide and its application to human liver disease. Eur J Clin Invest 1979; 9: 451–459
   PubMed Web of Science ®Google Scholar
• Burke MD. Liver function. Hum Pathol 1975; 6: 273–286
   PubMed Web of Science ®Google Scholar
• Brenner DA. Therapeutic strategies for hepatic fibrosis. Hepatology 1988; 8: 176–182
   PubMedGoogle Scholar
• Alcorn J, Chojkier M. Procollagen III peptide (PIIIP): can it reflect hepatic fibrosis?. Hepatology 1987; 7: 981–983
   Google Scholar
• Bentsen K D, Boesby S, Kirkegaard P, Hansen C P, Jensen S L, Horslev-Petersen K, Lorenzen I. Is the aminoterminal propeptide of type III procollagen degraded in the liver? A study of type III pro-collagen peptide in serum during liver transplantation in pigs. J Hepatol 1988; 6: 144–150
   PubMedGoogle Scholar
• Blum H E, Walter E, Offensperger S, Offensperger W B, Gerok W. Viral aetiology and pathogenesis of liver cirrhosis. Liver cirrhosis, J L Boyer, L Bianchi. MTP Press, Lancaster 1987; 119–138
   Google Scholar
• Chosegros P, Hartmann D, Adeleine P. In acute hepatitis circulating PIIINP and CIII are fibrosis markers, CI does not change [Abstract]. Gastroenterology 1988; 94: A530
   Google Scholar
• Yamada S, Suou T, Hirayama C. Clinical significance of serum hypoprotein and aminoterminal procollagen-III-peptide in liver disease. Pathobiology of hepatic fibrosis., C Hirayama, K I Kivirikko. Elsevier Science Publishers, Amsterdam 1985; 201–208
   Google Scholar
• Annoni G, Cargnel A, Colombo M, Hahn EG. Persistent elevation of the aminoterminal peptide of procollagen type III in serum of patients with acute viral hepatitis distinguishes chronic active hepatitis from resolving or chronic persistent hepatitis. J Hepatol 1986; 2: 379–388
   PubMed Web of Science ®Google Scholar
• Bentsen K D, Horslev-Petersen K, Junker P, Juhl E, Lorenzen I. Serum aminoterminal procollagen type III peptide in acute viral hepatitis. A long-term follow-up study. Liver 1987; 7: 96105
   Google Scholar
• Gressner A M, Kropf J. Estimation of the production rates of serum aminoterminal propeptide of type III procollagen and laminin in human fibrotic liver. J Clin Chem Clin Biochem 1987; 25: 553–559
   PubMedGoogle Scholar
• Johnson R L, Ziff M. Lymphokine stimulation of collagen accumulation. J Clin Invest 1976; 58: 240–252
   PubMed Web of Science ®Google Scholar
• Sato S, Leo M A, Lieber CS. Ultrastructural localization of type III procollagen in baboon liver. Am J Pathol 1986; 122: 212–217
   PubMed Web of Science ®Google Scholar
• Davis BH. Hepatic fibrogenesis: new developments? [Editorial]. Am J Gastroenterol 1987; 82: 544–546
   PubMedGoogle Scholar